Key TakeawaysModerna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by 1billion. Thestockbrokedownfromatwo−monthpennantpattern,settingthestageforapotentialcontinuationmovelower.InvestorsshouldwatchcrucialsupportlevelsonModerna′schartaround30 and 13,whilealsomonitoringkeyresistancelevelsnear57 and $68. Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plungin ...